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Abstract
Protein kinase inhibitors can be used as tools to identify proteins and pathways required for
virus replication. Using virus replication assays and western blotting we found that the
widely used protein kinase inhibitor BAY61-3606 inhibits replication of human cytomegalo-
virus (HCMV) strain AD169 and the accumulation of HCMV immediate-early proteins in
AD169 infected cells, but has no effect on replication of HCMV strain Merlin. Using in vitro
kinase assays we found that BAY61-3606 is a potent inhibitor of the cellular kinase IKKα.
Infection of cells treated with siRNA targeting IKKα indicated IKKα was required for efficient
AD169 replication and immediate-early protein production. We hypothesized that IKKα was
required for AD169 immediate-early protein production as part of the canonical NF-κB sig-
naling pathway. However, although BAY61-3606 inhibited phosphorylation of the IKKα sub-
strate IκBα, we found no canonical or non-canonical NF-κB signaling in AD169 infected
cells. Rather, we observed that treatment of cells with BAY61-3606 or siRNA targeting IKKα
decreased phosphorylation of histone H3 at serine 10 (H3S10p) in western blotting assays.
Furthermore, we found treatment of cells with BAY61-3606, but not siRNA targeting IKKα,
inhibited the accumulation of histone H3 acetylation (H3K9ac, H3K18ac and H3K27ac) and
tri-methylation (H3K27me3 and H3K36me3) modifications. Therefore, the requirement for
IKKα in HCMV replication was strain-dependent and during replication of an HCMV strain
requiring IKKα, IKKα-dependent H3S10 phosphorylation was associated with efficient
HCMV replication and immediate-early protein production. Plus, inhibition of HCMV replica-
tion by BAY61-3606 is associated with acetylation and tri-methylation modifications of his-
tone H3 that do not involve IKKα.
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Introduction
Cellular protein kinases are required for many aspects of viral replication and pathogenesis.
During human cytomegalovirus (HCMV) replication cellular proteins kinases have prominent
roles in genome replication as intracellular signaling pathways that contain protein kinases
have been implicated in activation of viral and cellular transcription during productive replica-
tion [1].
Productive HCMV transcription from the viral genome first requires activation of the
HCMV immediate early promoter (MIEP), which controls production of the immediate-early
viral proteins IE1 and IE2 [1]. These proteins stimulate a transcriptional cascade of immediate-
early to early to late RNA transcripts required for production of infectious virus [1]. The MIEP
is a complex promoter that can be recognized by transcription factors controlled by intracellu-
lar signaling pathways containing cellular protein kinases [1]. Perhaps the least understood,
and most controversial, signaling pathway reported to be involved viral transcription is the
canonical NF-κB signaling pathway.
During canonical NF-κB signaling [2] phosphorylation of serines in the IKKα/β heterodi-
mer (IKKα-P(Ser176/180)) leads to phosphorylation of the repressor protein IκBα at serine 32
(IκBα-P(Ser32)) by IKKα. Phosphorylation of IκBα triggers its proteasomal degradation. Deg-
radation of IκBα allows the release of a transcriptional activator heterodimer (RelA/p50)
bound to IκBα, which translocates from the cytoplasm to the nucleus and activates transcrip-
tion. RelA in the RelA/p50 heterodimer can be phosphorylated by a number of cellular kinase
proteins, which can dictate its function. This includes phosphorylation of RelA serine 536
(RelA-P(Ser536)) by kinases such as IKKα, IKKβ and IκBα [2,3]. Non-canonical NF-κB signal-
ing, which also requires IKKα, has also been described [2]. This pathway is dependent on the
proteasomal processing of the repressor protein p100 to p52, which is stimulated by phosphor-
ylation of p100 by IKKα. The absence of p100 allows the translocation of transcription factor
heterodimer RelB/p52 from the cytoplasm to the nucleus to activate transcription.
The role of canonical NF-κB signaling during productive HCMV replication is unclear. It
has been reported that deletion of NF-κB responsive elements in the MIEP has no effect on
productive HCMV replication [4] and canonical NF-κB signaling is not required for produc-
tive HCMV replication [5]. Conversely, it has also been reported that canonical NF-κB signal-
ing is required for transactivation of the MIEP [6], that there is up regulation of canonical NF-
κB responsive promoters in HCMV infected cells [7,8] and inhibition of canonical NF-κB sig-
naling impairs HCMV replication [6,9,10]. The role of canonical NF-κB signaling in activation
of cellular transcription during productive HCMV replication is also unclear, but it has been
reported that canonical NF-κB signaling is associated with transcription of cellular genes
involved in productive HCMV replication [11,12]. At least one previous report indicates that
non-canonical NF-κB signaling does not occur during productive HCMV replication [13].
Another factor in the control of HCMV gene expression is transcriptional regulation dic-
tated by histone proteins. This, also, is not well understood. During productive HCMV replica-
tion histones associate with the viral genome [14]. It has been reported that histone acetylation
is required for efficient viral gene transcription [14,15] and modifications of histone H3 most
commonly associated with active transcription, (acetylation of H3 at lysine 9 and lysine 14
(H3K9ac and H3K14ac, respectively)), are found at viral promoters, including the MIEP,
throughout productive HCMV replication [14]. The presence of these acetylation modifica-
tions is likely to be involved in the recruitment of transcription factors to chromatin.
The full catalogue of modifications that are present on histone H3 during productive
HCMV replication has yet to be determined. However, it is likely that phosphorylation of H3
occurs in HCMV infected cells as evidence from studies of uninfected cells points to a link
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between histone phosphorylation and acetylation. For example, H3 phosphorylation at residue
serine 10 (H3S10p) is related to the presence of H3K14ac on H3 [16] and there is a functional
relationship between the presence of H3S10p, H3K9ac and H3K14ac and the recruitment of
transcription factors to chromatin [17]. Interestingly, phosphorylation of H3 can be mediated
by IKKα [16,18–21], a protein kinase involved in both canonical and non-canonical NF-κB
signaling.
We sought to expand our understanding of intracellular signaling required for productive
HCMV replication. Previously, data from one of our laboratories using protein kinase inhibitor
BAY61-3606 suggested that germinal center kinase (GCK, also known as MAP4K2) can func-
tion upstream of NF-κB signaling [22]. It was unknown if GCK can affect NF-κB signaling in
HCMV infected cells. Therefore, we examined HCMV replication in the presence of BAY61-
3606.
Materials & Methods
Drugs
BAY61-3606 [23] and related compounds [22] were synthesized by the Gray laboratory or
obtained from SIGMA (UK). GCK inhibitors 5, 16, 17 have been previously described [24] and
were synthesized by the Gray laboratory. Maribavir [25] was a kind gift from John Drach (Uni-
versity of Michigan). All drugs were resuspended in dimethyl sulphoxide (DMSO). Tumor
necrosis factor alpha (TNF-α) and cycloheximide were kind gifts from Steve Goodbourn (St
George’s, University of London).
Cells and viruses
Human foreskin fibroblast (HFF) cells (clone Hs29) were obtained from American Type Cul-
ture Collection no. CRL-1684 (ATCC, Manassas, VA)). B cell line HB7 (an lymphoblastoid cell
line established by infection of adult B cells with the BAC-cloned B95-8 strain of EBV[26]) was
a kind gift from Robert White (Imperial College London) and lymphocyte cell line Jurkat was
obtained from the Dana-Farber Cancer Center, Boston, USA. All cells were maintained in Dul-
beccos Modified Eagles Medium (DMEM) (Gibco) containing 5% fetal bovine serum (FBS)
(Gibco), plus penicillin and streptomycin. High passage HCMV strain AD169 was a gift from
Don Coen (Harvard Medical School) and low passage strain Merlin(RCMV1111) (derived
from BACmid pAL1111, which does not express RL13 and UL128 [27]) was gift from Richard
Stanton (Cardiff University).
Viral yield reduction assays
Assays were performed essentially as described in [28]. HFF cells were plated at a density of
5 × 104 cells per well in 24-well plates. After overnight incubation, cells were infected with
HCMV at a multiplicity of infection (MOI) of 1. After virus adsorption for 1 hr at 37°C, cells
were washed and incubated with 1ml of media containing DMSO or BAY61-3606 at concen-
trations indicated in the text. Plates were incubated for 96 hours at 37°C. Titers were deter-
mined by serial dilution of viral supernatant onto HFF monolayers which were covered in
DMEMmedia containing 5% FBS and 0.6% methylcellulose. Cultures were incubated for 14
days, cells were stained with crystal violet and plaques were counted. All drug concentrations
were tested in duplicate. The final concentration of DMSO in all samples was maintained at
<1% (v/v).
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Plaque reduction assays
Assays were performed essentially as described in [28]. HFF cells were seeded at a density of
2 × 105 cells per well in 24-well plates. After 24 hours incubation, cells were infected with
HCMV at 40 PFU per well in DMEM plus 5% FBS at 37°C. One hour post-infection, the inoc-
ula were removed, cells were washed, and media containing various concentrations of DMSO
or BAY61-3606, 5% FBS and 0.6% methylcellulose were added. All drug concentrations were
tested in duplicate. After incubation at 37°C for 14 days, cell monolayers were stained with
crystal violet and plaques were counted. The final concentration of DMSO in all samples was
maintained at<1% (v/v).
Cytotoxicity assays
Assays were performed essentially as described in [28]. HFF cells were seeded at a density of
1 × 104 cells per well into 96-well plates. After 4 hours incubation to allow cell attachment, cells
were treated for the time indicated in the text with different concentrations of each compound
in duplicate. Cell viability was then determined with an MTT assay (GE Healthcare) according
to the manufacturer's protocol. The final concentration of DMSO in all samples was main-
tained at<1% (v/v). As a positive control, in all experiments a 2-fold dilution series of HFF
cells starting at 1 × 104 cells per well was included. In each experiment we found a linear rela-
tionship between the number of cells per well and output from the MTT assay (data not
shown).
Viral infection of HFF cells and treatment with drugs for Western blotting
analysis
5 x 104 or 1 x 105 HFF cells per well were seeded in 24- or 12-well plates, respectively, 24 hours
before infection. At the time of infection virus was added to each well at the MOI indicated in
the text. After incubation for 1 hour at 37°C, virus supernatant was removed and replaced
with 1 ml of complete Dulbeccos Modified Eagles Medium (DMEM) (Gibco) containing 5%
fetal bovine serum (FBS) (Gibco) containing either DMSO or drugs at the indicated concen-
trations. At indicated time points viral supernatant was titred onto HFF monolayers and/or
cells were washed once with PBS and resuspended in 100 μl Laemmli buffer containing 5% β-
mercaptoethanol.
Western blotting
Lysate from 5 x 103 or 1 x 104 cells was used to detect cellular and viral antigens, respectively.
Western blotting of proteins separated on 8% or 10% polyacrylamide gels was carried out as
described elsewhere [29], using antibodies recognizing IE1/2, UL44, pp28, UL84 (all Virusys,
1:1000 dilution), IE2 proteins (clone 5A8.2, Millipore, 1:1000 dilution), β-actin (SIGMA,
1:5000 dilution), SYK (ab3993) and GCK (ab167532 or ab184169) (all Abcam, 1:1000 dilution).
Antibodies recognizing UL112-113 proteins [30] or UL97 [31] were kind gifts from Shang-
Kwei Wang (Kaohsiung Medical University, Taiwan) and Donald Coen (Harvard Medical
School, USA), respectively. All antibodies recognizing proteins involved in NF-κB signaling or
H3 proteins were obtained from Cell Signaling Technology (products #9936, #4888, #9927,
#9847, #9783) and used as per the suppliers instructions. All primary antibodies were detected
using anti-mouse- or anti-rabbit-horseradish peroxidase (HRP) conjugated antibodies (Milli-
pore and Cell Signaling Technology, respectively). Chemiluminescence solution (GE Health-
care) was used in each case to detect secondary antibodies using film. The intensity of certain
bands detected by western blotting was assessed using Photoshop CS4. To compare band
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intensity, the mean intensity from an identical area around each band was found and sub-
tracted from a “blank” area on the same blot. Data shown is the band intensity normalized to
the β-actin controls shown in each lane of that figure expressed as arbitrary units (a.u.).
Transfection of siRNA into HFF cells
Briefly, 1 x 105 HFF per well were seeded in 12-well plates 24 hours before transfection in
DMEM+5%FBS with no antibiotics. siControl Non targeting siRNA #3, ON-TARGETplus
SMARTpool Human GCK or ON-TARGETplus SMARTpool Human IKKα (all Dharmacon)
were used. Per well, 113 μl of 1 μM siRNA and 2 μl Dharmafect2 (Dharmacon) were diluted in
93 μl and 146 μl Optimem (Invitrogen), respectively. After 5 mins at room temperature, both
solutions were combined. After 20 mins, media was removed from each well and replaced with
the siRNA/Dharmafect mixture then 500 μl of DMEM+5%FBS with no antibiotics was added
to each well. Transfected cells were incubated at 37°C for 72 hours then either prepared for
western blotting or infected as indicated in the text.
To ensure that IKKα siRNAs do not non-specifically bind to either viral or cellular mRNAs,
interaction of each siRNA from the IKKα siRNA pool was analyzed using online genome-wide
enrichment of seed sequence mapping (GESS) (http://www.flyrnai.org/gess/). We found no
obvious off-target binding of any IKKα siRNA to any cellular mRNA or any mRNA transcript
expressed from the AD169 genome (data not shown).
In vitro analysis of kinase activity
All assays were conducted using the KinaseProfiler™ service Eurofins Pharma Discovery Ser-
vices UK Limited. Briefly, recombinant protein kinases were purified from baculovirus cells
and purified by affinity chromatography using the proteins tags mentioned below. Each kinase
was resuspended in 50 mM TRIS, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% β-mercaptoethanol,
1 mg/mL BSA (SYK, LYN) or 20 mMMOPS, 1 mM EDTA, 0.01% Brij-35, 5% Glycerol, 0.1%
β-mercaptoethanol, 1 mg/mL BSA (GCK, IKKα, IKKβ). In each reaction;
1. SYK. Full length His-tagged protein was used. Kinase was incubated with 50 mM Tris pH
7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% β-mercaptoethanol, 0.1 mg/ mL poly(Glu, Tyr)
4:1, 10 mMMgAcetate and [γ-33P-ATP].
2. GCK. Residues 1–473 glutathione-s-transferase (GST) tagged protein was used. Kinase was
incubated with 8 mMMOPS pH 7.0, 200 mMNaCl, 0.2 mM EDTA, 0.8 mg/mL MBP, 10
mMMgAcetate and [γ-33P-ATP].
3. IKKα. Full length GST-tagged protein was used. Kinase was incubated with 8 mMMOPS
pH 7.0, 0.2 mM EDTA, 200 μM peptide, 10 mMMgAcetate and [γ-33P-ATP].
4. IKKβ. Full length His-tagged protein was used. Kinase was incubated with 8 mMMOPS pH
7.0, 0.2 mM EDTA, 100 μM peptide, 10 mMMgAcetate and [γ-33P-ATP].
5. Lyn. Full length His-tagged protein was used. Kinase was incubated with 50 mM Tris pH
7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% β-mercaptoethanol, 0.1 mg/mL poly(Glu, Tyr)
4:1, 10 mMMgAcetate and [γ-33P-ATP].
In each reaction the specific activity of [γ-33P-ATP] was approximately 500 cpm/pmol.
Each reaction was initiated with the addition of 10 μMMgATP. After incubation for 40 min-
utes at room temperature, reactions were stopped with the addition of 3% phosphoric acid.
Ten μL of the reaction is then spotted onto Filtermat A or P30 filtermat and washed three
times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and
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scintillation counting. As indicated in the text and Figure Legends, in each reaction 10 μM
BAY61-3606 or the equivalent volume of DMSO was added to reactions containing each pro-
tein kinase. To determine IC50 concentrations, a range of BAY61-3606 concentrations (100–
0.01 μM) or the equivalent volumes of DMSO were added to reactions containing IKKα. IC50
data was analyzed using XLFit version 5.3 (ID Business Solutions). To calculate IC50 values
sigmoidal dose-response (variable slope) curves were fitted using non-linear regression
analysis.
Results
Inhibition of HCMV replication and immediate-early protein production
by BAY61-3606
We employed viral yield reduction and viral plaque reduction assays to assess the ability of
BAY61-3606 to inhibit replication of HCMV strain AD169 in human foreskin fibroblast (HFF)
cells. AD169 is a high passage HCMV strain that has previously been used to study nearly all
aspects of HCMV replication [32]. In both assays we found 50% Effective Dose and 90% Effec-
tive Dose (ED50 and ED90, respectively) values in the range of 0.2–1.2 μM (Table 1). These
values are similar to those for inhibition of HCMV replication by the frontline therapy drug
ganciclovir [28,33], indicating BAY61-3606 is an effective inhibitor of HCMV replication. To
exclude the possibility that the observed reduction in HCMV replication is due to BAY61-3606
toxicity in HFF cells, we exposed HFF cells to BAY61-3606 at a range of concentrations and
used an MTT dye-uptake assay to assess cell viability. This assay indicated that BAY61-3606
had a 50% Cytotoxicity Concentration (CC50) value of greater than 100 μM (Table 1). Thus,
the ability of BAY61-3606 to inhibit AD169 replication is unlikely to be due to drug toxicity in
HFF cells.
We also used the viral yield reduction assay to asses the ability of BAY61-3606 to inhibit
replication of HCMV strain Merlin(RCMV1111) [27] in HFF cells. Merlin is low passage strain
of HCMV whose genomic content is more similar to wild type HCMV than high passage
HCMV strains such as AD169 [32]. We found that BAY61-3606 did not obviously inhibit Mer-
lin(RCMV1111) replication at concentrations up to 10μM (Table 1). Therefore, the ability of
BAY61-3606 to inhibit HCMV replication differs between strains of HCMV.
To investigate how BAY61-3606 inhibits AD169 replication we used western blotting to
analyze the presence of immediate-early (IE1/IE2), early (UL44) and late (pp28) viral proteins
in HFF cells infected with AD169 and treated with either DMSO or BAY61-3606 (Fig 1). We
observed a 2- to 3-fold reduction in the accumulation of IE1, IE2, UL44 and pp28 in AD169
infected cells treated with BAY61-3606 at 72 h.p.i. (Fig 1A, lanes 5–7), compared to those
Table 1. Viral inhibition and cytotoxicity assays using BAY61-3606.
BAY61-3606
Assay Viral Strain ED501 ED901 CC501
Viral Yield Reduction2 AD169 0.5 1.2 -
Viral Yield Reduction2 Merlin(RCMV1111) >10 >10 -
Viral Plaque Reduction2 AD169 0.2 0.4 -
MTT Cytotoxicity3 - - - >100
1 μM
2Viral titre was assessed at 96 hours infection in the presence of drug.
3MTT assays were carried out after 96 exposure of cells to drug.
doi:10.1371/journal.pone.0150339.t001
IKKα Phosphorylation of H3 in HCMV Infected Cells
PLOS ONE | DOI:10.1371/journal.pone.0150339 March 1, 2016 6 / 22
Fig 1. Analysis of viral proteins in HCMV infected HFF cells treated with DMSO or BAY61-3606. (A and
B) HFF cells were uninfected or infected with AD169 at an MOI of 1, then treated with either 1μMBAY61-
3606 or the equivalent volume of DMSO. Cell lysates were prepared for western blotting at the time points
(hours post infection (h.p.i.)) indicated above the figures. Uninfected cells harvested at the time of infection
are shown as 0 h.p.i.. Proteins recognized by the antibodies used in each experiment are indicated to the
right of each figure. The positions of molecular weight markers (kDa) are indicated to the left of each figure. In
Fig 1A the band intensities are expressed in arbitrary units below each panel.
doi:10.1371/journal.pone.0150339.g001
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treated with DMSO (Fig 1A, lanes 2–4). In this and subsequent western blotting experiments
the amount of β-actin in each sample was also assayed to demonstrate equivalent loading of
samples in each lane. We hypothesized that BAY61-3606 reduces accumulation of the immedi-
ate-early proteins IE1 and IE2, which leads to a reduction in UL44 and pp28. This was sup-
ported by further western blotting experiments (Fig 1B). Compared to treatment of AD169
infected cells with DMSO (Fig 1B, lanes 2–4), the treatment of infected cells with BAY61-3606
(Fig 1B, lanes 5–7) inhibited the accumulation of IE2 (IE2-86) and IE2 proteins that are
expressed late in replication (IE2-60 and IE2-40 [34]), plus the accumulation of proteins pro-
duced from the viral UL112-113 (p84, p50, p43, p34) locus whose expression is dependent on
transcriptional activation by IE2 [35] and viral protein UL84, whose post-translational stability
requires the presence of IE2 [36,37]. In each case a 2- to 4-fold decrease was found by analyzing
band intensity, except for IE2 proteins, which showed an over 5-fold decrease at 72 h.p.i. (data
not shown). Therefore, treatment of AD169 infected HFF cells with BAY61-3606 results in
inhibition of viral immediate early protein accumulation. Furthermore, treatment of AD169
infected cells with BAY61-3606 at the time of infection results in a dramatic decrease in viral
replication (Table 1), but a more modest decrease in immediate-early protein production (Fig
1A and 1B). Therefore, inhibition of viral replication by BAY61-3606 is likely to inhibit the
production or function of viral or cellular factors required for productive replication other
than viral immediate-early proteins.
Potential BAY61-3606 targets in HCMV infected cells
We hypothesized that GCK is a target of BAY61-3606 in HFF cells infected with AD169. To
assess if GCK is required for productive HCMV replication we treated HFF cells with either
siRNA targeting GCKmRNA (GCK siRNA) or a control siRNA that has no target in human
cells (Ctrl siRNA). We then infected siRNA treated cells with AD169 and either used western
blotting to assess GCK protein levels or assayed production of HCMV (Fig 2A and 2B, respec-
tively). While we observed a reduction in GCK in infected cells treated with GCK siRNA (Fig
2A, lane 2) compared to Ctrl siRNA (Fig 2A, lane 1), we found no difference in production of
HCMV from HFF cells treated with either Ctrl siRNA or GCK siRNA (Fig 2B). Furthermore,
we also treated AD169 infected HFF cells with either potent and specific inhibitors of GCK
structurally unrelated to BAY61-3606 (compounds 5, 16 and 17 [24]), BAY61-3606 or DMSO
and found that only BAY61-3606 inhibited AD169 replication (Fig 2C). Therefore, as removal
or inhibition of GCK had no effect on productive AD169 replication it is unlikely GCK is the
target of BAY61-3606 in this context.
BAY61-3606 has been reported to inhibit the cellular kinase protein spleen tyrosine kinase
(SYK) [23]. Using western blotting (Fig 2D) we could detect SYK in the lymphocyte cell line
Jurkat (Fig 2D, lane 1), but not in either uninfected or AD169 infected HFF cells (Fig 2D, lanes
2 and 3, respectively). Therefore, SYK is unlikely to be a target of BAY61-3606 in AD169
infected HFF cells.
As BAY61-3606 is a kinase inhibitor we also investigated the possibility that the drug can
inhibit the virally encoded kinase UL97. The mobility of UL97 from AD169 infected HFF cells
treated with either DMSO, BAY61-3606 or the UL97 kinase inhibitor maribavir [25] in a poly-
acrylamide gel was assayed using western blotting (Fig 2E). We found that UL97 in AD169
infected cells treated with maribavir (Fig 2E, lane 4) had a molecular weight less than UL97 in
infected cells treated with either DMSO or BAY61-3606 (Fig 2E, lanes 2 and 3, respectively).
As maribavir can inhibit UL97 autophosphorylation [38], we propose that while maribavir can
inhibit UL97 phosphorylation, resulting in the detection of low molecular weight unpho-
sphorylated UL97, the presence of neither DMSO nor BAY61-3606 affected the protein kinase
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activity of UL97. As UL97 is produced late in HCMV replication, the low levels of UL97 in
HCMV infected cells treated with either maribavir or BAY61-3606 compared to infected cells
treated with DMSO, is likely due to inhibition of immediate-early protein production by these
drugs (Fig 1 and [39]).
Inhibition of IKKα kinase activity by BAY61-3606
One of our laboratories has previously examined the ability of BAY61-3606 to inhibit a broad
range of cellular kinases [22]. We reassessed this data and noted that the greatest inhibitory
effect of BAY61-3606 was directed against the cellular kinase protein IKKα. Furthermore, we
observed that a series of drugs structurally related to BAY61-3606 that do not inhibit IKKα
(BAY1, BAY6, BAY8, BAY21 and BAY28 [22]) had no effect on AD169 replication (Fig 3A).
Therefore, we hypothesized that IKKαmay be required for productive AD169 replication.
Fig 2. Investigation of roles for SYK and GCK in HCMV infected cells. (A and B) Analysis of siRNA treated cells infected with AD169. HFF were treated
with the siRNAs indicated in each figure for 72 hours and infected with 1x105 plaque forming units (p.f.u.) of HCMV. At 96 h.p.i cell lysates were prepared for
western blotting (Fig 2A) and viral supernatants were harvested for virus titration (Fig 2B). In Fig 2B viral titre is expressed as plaque forming units/ml (p.f.u./
ml) and the mean and standard deviation of 3 experiments is shown. (C) Analysis of HCMV infected cells treated with inhibitors of GCK. HFF cells were
infected with AD169 at an MOI of 1 then treated with 1μM of the drug indicated in the figure or the equivalent volume of DMSO. Viral supernatants were
harvested at the indicated time points and viral titre (p.f.u./ml) at each time point was determined. (D and E) Western blotting of lysate from uninfected or
infected cell lines. Unless stated otherwise, all lysates are from HFF cells. Where indicated, HFF cells were either uninfected or infected with AD169 at an
MOI of 1 then treated with either 1μMBAY61-3606, 1μMMaribavir or the equivalent volume of DMSO. Cell lysates were prepared for western blotting at 72
hours post infection. In each panel showing western blotting proteins recognized by the antibodies used in each experiment are indicated to the right of each
figure and the positions of molecular weight markers (kDa) are indicated to the left of each figure.
doi:10.1371/journal.pone.0150339.g002
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Fig 3. Identification of IKKα as a target of BAY61-3606. (A) Inhibition of AD169 replication by BAY compounds. HFF cells were infected with AD169 at an
MOI of 1 then treated with 1μM of the drug indicated in the figure or the equivalent volume of DMSO. Viral supernatants were harvested at 96 h.p.i. and viral
titre (p.f.u./ml) was determined. (B and C) In vitro kinase assays in the presence of BAY61-3606. The ability of 10 μMBAY61-3606 (Fig 3B) or a range of
BAY61-3606 concentrations (Fig 3C) to inhibit the kinase activity of each of the indicated kinase proteins was assayed. Each data point in each figure
represents the percentage kinase activity in the presence of drug compared to DMSO treated controls. Each data point shows the mean value of two
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To confirm BAY61-3606 is an inhibitor of IKKα we used in vitro kinase assays to assess the
ability of BAY61-3606 to inhibit the kinase activity of a number of cellular kinases, including
IKKα. We observed that BAY61-3606 is a potent inhibitor of SYK, GCK and IKKα, but not
IKKβ or LYN, a kinase functionally unrelated to IKKα (Fig 3B). We also quantified the ability
of BAY61-3606 to inhibit IKKα by measuring kinase activity in in vitro kinase assays over a
range of drug concentrations (Fig 3C). We found that BAY61-3606 could inhibit IKKα kinase
activity with a sub-micromolar 50% inhibitory concentration (IC50) (0.045 μM), indicating
that BAY61-3606 is a potent IKKα kinase inhibitor.
To investigate the role of IKKα in HCMV replication, we treated HFF cells with either Ctrl
siRNA or siRNA targeting IKKαmRNA (IKKα siRNA) and assayed either the presence of
IKKα protein using western blotting or AD169 replication (Fig 3D and 3E, respectively). We
observed that treatment of HFF cells with IKKα siRNA (Fig 3D, lane 2 and Fig 4E) notably
depleted IKKα and lowered AD169 production by 3-fold and 10-fold, respectively, compared
to HFF cells treated with Ctrl siRNA (Fig 3D, lane 1 and Fig 3E).
To complement these findings, we used western blotting to assay production of immediate-
early proteins IE1 and IE2 in siRNA treated cells infected with HCMV (Fig 3F). At 24 h.p.i. we
observed that accumulation of IE2 was approximately 4-fold lower in infected HFF cells treated
with IKKα siRNA (Fig 3F, lane 2) compared to infected HFF cells treated with Ctrl siRNA (Fig
3F, lane 1). We also performed serial dilution of these samples and again assayed IE1 and IE2
protein levels by western blotting (Fig 3G). Here we observed approximately 3- to 5-fold reduc-
tion in accumulation of both IE1 and IE2 proteins in AD169 infected HFF cells treated with
IKKα siRNA (Fig 3G, lanes 5–8) compared to AD169 infected HFF cells treated with Ctrl
siRNA (Fig 3G, lanes 2–4) at various dilations. We observed similar phenotypes when infected
cell lysates prepared at 48 and 72 h.p.i were analyzed for IE1 and IE2 levels by western blotting
(data not shown).
Therefore, we confirm that BAY61-3606 is an inhibitor of IKKα and provide quantitative
analysis of IKKα kinase inhibition by BAY61-3606. Similar phenotypes are observed upon
treatment of AD169 infected HFF cells with BAY61-3606 and during AD169 replication in
HFF cells treated with IKKα siRNA. Therefore, we propose that IKKα is a target of BAY61-
3606 in AD169 infected HFF cells. Furthermore, treatment of AD169 infected cells with IKKα
siRNA results in a greater decrease in viral replication compared to the observed decrease in
immediate-early protein production. Therefore, inhibition of viral replication by IKKα siRNA
is likely to inhibit the production or function of viral or cellular factors required for productive
replication other than viral immediate-early proteins. This could include factors affected by the
depletion of IKKα before infection.
Canonical and non-canonical NF-κB signaling in uninfected and infected
cells
To confirm that BAY61-3606 can act as an inhibitor of IKKα in HFF cells we assayed the abil-
ity of BAY61-3606 to inhibit canonical NF-κB signaling stimulated by TNF-α treatment in
uninfected HFF cells (Fig 4A). HFF cells were untreated (Fig 4A, lane 4) or pretreated for 16
experiments. (D-G) Analysis of HFF treated with siRNA. HFF cells were treated with either Crtl or IKKα siRNA. After 72 hours incubation with siRNA cell
lysates were prepared for western blotting (Fig 3D) or infected with 1x105 p.f.u. of HCMV to analyze virus replication by virus titration (Fig 3E). The data in Fig
3E is represented as p.f.u./ml at 96 h.p.i. and shows the mean and standard deviation of 3 experiments. Also, cell lysates from siRNA treated cells infected
AD169 were prepared for western blotting 24 h.p.i. (Fig 3F). In Fig 3G, samples from lanes 1 and 5 of Fig 3E were diluted in a 2-fold series (lanes 2–4 and
6–8, respectively). The siRNA used in each case is indicated in each panel. In Fig 3D, 3F and 3G proteins recognized by the antibodies used in each
experiment are indicated to the right of each figure and the positions of molecular weight markers (kDa) are indicated to the left of each figure. Band
intensities are expressed in arbitrary units above or below each panel.
doi:10.1371/journal.pone.0150339.g003
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Fig 4. Investigation of canonical and non-canonical NF-κB signaling. (A) Canonical NF-κB signaling in uninfected HFF cells treated with TNF-α. Lysates
of HFF cells prepared for western blotting after pre-treatment with either 1μMBAY61-3606 or the equivalent volume of DMSO and then treated with 10 ng/ml
TNF-α for 5 mins. The number of hours pre-treatment (h.pre.t.) with DMSO or BAY61-3606 is indicated above the Fig 4A. Where cells were simultaneously
treated with TNF-α and either DMSO or BAY61-3606 is indicated as 0 h.p.t. (B) Canonical NF-κB signaling in uninfected and infected HFF cells. HFF cells
were uninfected or infected with AD169 at an MOI of 1, then treated with either 1μMBAY61-3606 or the equivalent volume of DMSO. Cell lysates were
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hours or 1 hour with either DMSO or BAY61-3606 before TNF-α treatment (Fig 4A, lanes 1–2
and lanes 5–6, respectively) or treated with either DMSO or BAY61-3606 at the time of TNF-α
treatment (Fig 4A, lanes 3 and 7, respectively). After treatment of cells, cell lysates were pre-
pared for western blotting and analyzed using antibodies that recognize components of the
canonical NF-κB signaling pathway.
Treatment of cells with TNF-α and DMSO resulted in accumulation of IKKα/β-P(Ser176/
180) and phosphorylation of the IKKα substrate IκBα (IκBα-P(Ser32)). Furthermore, IκBα,
was present at low levels and increased in molecular weight, which is consistent with phosphor-
ylation dependent activation of IκBα proteasomal degradation. Finally, consistent with activa-
tion of canonical NF-κB signaling, we observed increased levels RelA-P(Ser536). Treatment of
cells with TNF-α and BAY61-3606 resulted in a loss of IKKα/β-P(Ser176/180), IκBα-P(Ser32),
but no obvious difference in accumulation of IκBα. Also, treatment of cells with BAY61-3606
had no obvious effect on accumulation of RelA-P(Ser536). Therefore, the presence of BAY61-
3606 is sufficient to inhibit phosphorylation of IκBα by IKKα in TNF-α treated HFF cells,
although this is not sufficient to inhibit canonical NF-κB signaling under experimental condi-
tions used here.
We hypothesized that treatment of HCMV infected cells with BAY61-3606 would lead to
inhibition of canonical NF-κB signaling. Therefore, we assayed canonical NF-κB signaling in
uninfected HFF cells (Fig 4B, lane 1) and HFF cells infected with AD169 and treated with either
DMSO or BAY61-3606 (Fig 4B, lanes 2–4 and lanes 5–7, respectively). We found no IKKα-P
(Ser176/180) in any sample. Moreover, although the presence of BAY61-3606, but not DMSO,
decreased levels of IκBα-P(Ser32) we found no degradation of IκBα that would indicate canon-
ical NF-κB signaling had occurred. Also, accumulation of RelA-P(Ser536) in AD169 infected
cells treated with either DMSO or BAY61-3606 increased over time. Thus, while the presence
of BAY61-3606 can inhibit phosphorylation of IκBα by IKKα in HCMV infected cells, lack of
IKKα/β phosphorylation and lack of IκBα degradation indicates canonical NF-κB signaling
does not occur. However, accumulation of RelA-P(Ser536) suggests that there may be tran-
scriptional transactivation by RelA outside of canonical NF-κB signaling.
It has been reported that NF-κB signaling in HCMV infected cells occurs early in HCMV
infection [6–8,12,40]. We, therefore, assayed degradation of IκBα by western blotting in unin-
fected HFF cells (Fig 4C, lane 1), uninfected HFF cells treated with TNF-α (Fig 4C, lane 2) or
HFF cells infected with AD169 and treated with DMSO or BAY61-3606 from 4–24 h.p.i. (Fig
4C, lanes 3–5 and 6–8, respectively). We found degradation of IκBα in uninfected cells treated
with TNF-α, but not in uninfected cells or infected cells treated with either DMSO or BAY61-
3606.
As canonical NF-κB signaling results in production of IκBα [41], we also considered the
possibility that canonical NF-κB signaling occurs in AD169 infected cells but de novo produc-
tion of IκBαmasks degradation of IκBα. We, therefore, investigated if IκBα was degraded in
prepared for western blotting at the time points (hours post infection (h.p.i.)) indicated above the figure. Uninfected cells harvested at the time of infection are
shown as 0 h.p.i.. (C) Analysis of IκBα degradation at early time points. HFF cells were uninfected (0 h.p.i.) (lane 1), uninfected and treated with 10 ng/ml
TNF-α for 5 minutes (lane 2), or infected with AD169 at an MOI of 1, then treated with either 1μMBAY61-3606 or the equivalent volume of DMSO (lanes 6–8
and 3–5, respectively). Cell lysates were prepared for western blotting at the time points (hours post infection (h.p.i.)) indicated above the figure. (D) Analysis
of cycloheximide treatment on IκBα degradation. HFF cells were infected with AD169 at an MOI of 1 then treated with either 1μMBAY61-3606 or the
equivalent volume of DMSO for 72 hours. At 72 h.p.i. cell lysates were prepared for western blotting after treatment with 100 μg/ml cycloheximide for the time
points (hours post treatment (h.po.t.)) indicated above the figure. (E) Non-canonical NF-κB signaling in uninfected and infected HFF cells. HFF cells were
uninfected or infected with AD169 at an MOI of 1, then treated with either 1μMBAY61-3606 or the equivalent volume of DMSO. Cell lysates were prepared
for western blotting at the time points (hours post infection (h.p.i.)) indicated above the figure. Uninfected cells harvested at the time of infection are shown as
0 h.p.i.. An equivalent volume of lysate from the EBV infected B cell line HB7 was also analyzed. Where indicated, uninfected cells harvested at the time of
infection are shown as 0 h.p.i.. In each figure proteins recognized by the antibodies used in each experiment are indicated to the right of each figure. The
positions of molecular weight markers (kDa) are indicated to the left of each figure.
doi:10.1371/journal.pone.0150339.g004
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HFF cells infected with AD169 and treated with the protein synthesis inhibitor cycloheximide
in the presence of either DMSO or BAY61-3606 (Fig 4D, lanes 2–4 and lanes 6–8, respectively).
We did not observe degradation of IκBα under any condition. Therefore, while IκBα phos-
phorylation can occur in HCMV infected HFF cells a mechanism exists which prevents degra-
dation of IκBα, which is essential for canonical NF-κB signaling. This would further indicate
that canonical NF-κB signaling does not occur in this context and that IKKα is involved in a
mechanism other than canonical NF-κB signaling that is required for productive HCMV
replication.
IKKα is also required for non-canonical NF-κB signaling. Proteasomal processing of p100
to p52 is required for non-canonical NF-κB signaling. We used western blotting to assay levels
of p100 and p52 in uninfected HFF cells (Fig 4E, lane 1), HFF cells infected with AD169 then
treated with either DMSO or BAY61-3606 (Fig 4E, lanes 2–4 and 5–7, respectively), or the
EBV positive B cell line HB7 (Fig 4E, lane 8) in which non-canonical NF-κB signaling should
occur [42]. Processing of p100 and p52 was observed in HB7 cells but not uninfected or
infected HFF cells. Thus, consistent with a previous report [13], non-canonical NF-κB signal-
ing does not appear to occur in AD169 infected cells. Therefore, IKKα is involved in a mecha-
nism required for productive AD169 replication other than non-canonical NF-κB signaling.
Requirement of IKKα for H3 serine 10 phosphorylation
IKKα has been reported to phosphorylate histone H3 at serine residue 10 (H3S10p) [16,18–
21]. Therefore, we used western blotting to investigate H3S10 phosphorylation in uninfected
HFF cells (Fig 5A, lane 1) and HFF cells infected AD169 and treated with either DMSO or
BAY61-3606 (Fig 5A, lanes 2–4 and 5–7, respectively). Histone H3 levels were equivalent
between samples, however, we observed a notable decrease in H3S10p in infected cells treated
with BAY61-3606 compared to infected cells treated with DMSO. Therefore, IKKα was likely
required for H3S10 phosphorylation in AD169 infected HFF cells. Using western blotting we
assayed H3S10 phosphorylation in uninfected and infected cells treated with either Ctrl siRNA
or siRNA targeting IKKα (IKKα siRNA) (Fig 5B, lanes 1–4 and 5–8, respectively). Treatment
of cells with IKKα siRNA depleted IKKα compared to cells treated with Ctrl siRNA. Levels of
H3 were equivalent in all samples, however, we found less H3S10p in cells treated with IKKα
siRNA compared to cells treated with Ctrl siRNA (approximately 6-fold and 16-fold decreases
at 48 and 72 h.p.i., respectively). Therefore, IKKα is required for H3S10p in AD169 infected
HFF cells and loss of H3S10p could result in inhibition of productive AD169 replication.
The relationship between H3 phosphorylation, acetylation and
methylation in HCMV infected cells
Loss of H3S10p has been reported to result in loss of acetyl modifications of H3 [16,21] and at
least one study indicates that loss of H3S10p reduces the total levels of H3K14ac in cells [16].
As the presence of H3K14ac on H3 is associated with transcriptional activation in HCMV
infected cells [14], we hypothesized that loss of H3S10p might also lead to loss of H3K14ac,
which would impact HCMV gene expression. We used western blotting to assay levels of H3,
H3S10p and acetylation of H3 on a number of commonly studied H3 residues including K14
(H3K9ac, H3K14ac, H3K18ac, H3K27ac) in either uninfected HFF cells (Fig 6A, lane 1) or
HFF cells infected with AD169 and treated with either DMSO or BAY61-3606 (Fig 6A, lanes
2–4 and 5–7, respectively). Levels of H3 were equivalent in all samples and treatment of
HCMV infected cells with BAY61-3606, but not DMSO, lowered levels of H3S10p. There was
little or no difference in accumulation of H3K14ac in infected cells treated with either DMSO
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or BAY61-3606. However, BAY61-3606 inhibited accumulation of H3K9ac, H3K18ac and
H3K27ac.
To asses what differences in H3K9ac, H3K18ac, H3K27ac accumulation were attributable to
inhibition of IKKα, we used western blotting to assay H3 acetylation levels in HFF cells treated
with either Ctrl or IKKα siRNA and infected with AD169 (Fig 6B). While treatment of HFF
cells with IKKα siRNA (Fig 6B, lane 2) decreased IKKα levels compared to cells treated with
DMSO (Fig 6B, lane 1), we observed no obvious difference between H3K9ac, H3K18ac or
H3K27ac.
Therefore, in AD169 infected cells treated with BAY61-3606 loss of H3S10p did not lead to
loss of H3K14ac. However, the accumulation of BAY61-3606 decreased H3K9ac, H3K18ac or
H3K27ac, which may contribute to the anti-HCMV effects of BAY61-3606. However, as loss of
Fig 5. Analysis of H3 phosphorylation by IKKα. (A) Analysis of H3S10p in HCMV infected HFF cells
treated with BAY61-3606. HFF cells were uninfected or infected with AD169 at an MOI of 1, then treated with
either 1μMBAY61-3606 or the equivalent volume of DMSO. Cell lysates were prepared for western blotting
at the time points (hours post infection (h.p.i.)) indicated above the figure. Uninfected cells harvested at the
time of infection are shown as 0 h.p.i.. Short and a long exposures of the western blot to film to detect H3S10p
are shown. (B) Analysis of H3S10p in infected cells treated with siRNA. HFF cells were treated with either Crtl
or IKKα siRNA. After 72 hours incubation with siRNA cells were prepared for western blotting (0 h.p.i.) or
infected with 1x105 p.f.u. of AD169 and then prepared for western blotting at the time points (h.p.i.) indicated
above the figure. The siRNA used are also indicated above the figure. In each figure proteins recognized by
the antibodies used in each experiment are indicated to the right of each figure. The positions of molecular
weight markers (kDa) are indicated to the left of each figure. In Fig 5B band intensities are expressed in
arbitrary units below certain panels.
doi:10.1371/journal.pone.0150339.g005
IKKα Phosphorylation of H3 in HCMV Infected Cells
PLOS ONE | DOI:10.1371/journal.pone.0150339 March 1, 2016 15 / 22
Fig 6. Investigation of histone H3modifications in BAY61-3606 and siRNA treated cells. (A, C and D) Western blotting of HFF cells treated with BAY61-
3606. HFF cells were uninfected or infected with AD169 at an MOI of 1, then treated with either 1μMBAY61-3606 or the equivalent volume of DMSO. Cell
lysates were prepared for western blotting at the time points (hours post infection (h.p.i.)) indicated above the figure. Uninfected cells harvested at the time of
infection are shown as 0 h.p.i.. (B) Western blotting of HFF cells treated with siRNA. HFF cells were treated with either Crtl or IKKα siRNA. After 72 hours
incubation cells infected with 1x105 p.f.u. of AD169 and then prepared for western blotting at 72 h.p.i.. The siRNA used is indicated above the figure. In each
figure proteins recognized by the antibodies used in each experiment are indicated to the right of each figure. The positions of molecular weight markers
(kDa) are indicated to the left of each figure.
doi:10.1371/journal.pone.0150339.g006
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IKKα has no effect on H3K9ac, H3K18ac or H3K27ac, it is unlikely H3S10p is required to
maintain these post-translational modifications of histone H3.
It is unknown what relationship, if any, there may be between H3S10p levels and levels of
dimethylation (me2) and trimethylation (me3) of H3 in HCMV infected cells. Western blotting
was used to assay H3, H3S10p, plus H3 dimethylation (H3K4me2, H3K27me2, H3K36me2,
H3K79me2) or H3 trimethylation (H3K4me3, H3K9me3, H3K27me3, H3K36me3) in unin-
fected HFF cells (lane 1, Fig 6C and 6D, respectively) or HFF cells infected with AD169 in the
presence of either DMSO or BAY61-3606 (lanes 2–4 and 5–7, Fig 6C and 6D, respectively). In
both experiments H3 was equivalent in all samples and treatment of HCMV infected cells with
BAY61-3606, but not DMSO, lowered levels of H3S10p. We found no obvious difference
between DMSO and BAY61-3606 treatment in accumulation of any me2 modification exam-
ined. However, there was a decrease in H3K27me3 and H3K36me3 accumulation in cells
treated with BAY61-3606 compared to DMSO treated cells. Also, we observed a difference in
H3K4me3 accumulation in BAY61-3606 treated cells early, but not late in infection compared
to DMSO treated cells. There was no obvious difference in H3K9me3 in infected cells treated
with either DMSO or BAY61-3606.
We decided to focus on H3K27me3 and H3K36me3 modifications and again used siRNA to
determine if IKKα is required for H3K27me3 and H3K36me3 modifications of H3 in AD169
infected cells (Fig 6B). We found no obvious difference when we compared H3K27me3 and
H3K36me3. Therefore, in AD169 infected cells treated with BAY61-3606 inhibition of
H3K27me3 and H3K36me3 accumulation could contribute to the anti-HCMV effects of
BAY61-3606. Thus, BAY61-3606 can inhibit virus replication via pathways that do not involve
IKKα. Furthermore, as loss of IKKα has no effect on H3K27me3 or H3K36me3 it is unlikely
H3S10p is required to maintain these post-translational modifications of histone H3.
Discussion
Our studies of BAY61-3606 targets and mechanism of action of reveal unexpected insights
about the role of IKKα and intracellular signaling in HCMV infected cells. First, we considered a
role for IKKα in NF-κB signaling in HCMV infected cells. The role of canonical NF-κB signaling
in productive HCMV replication has been unclear as there are reports indicating canonical NF-
κB signaling is either required [6], or not required [4,5], for productive HCMV replication. Our
observations are consistent with previous reports that canonical NF-κB signaling is not required
for productive AD169 replication [4,5] and we provide data indicating how canonical NF-κB
signaling is compromised during AD169 infection. The lack of IKKα/β phosphorylation and
lack of IκBα degradation indicates that canonical NF-κB signaling does not occur in our studies
of AD169 infected cells. Inhibition of IKKα/β phosphorylation may be due to the presence of
the viral protein UL26, which has recently been reported to antagonize IKKα/β phosphorylation
[13]. However, we observe phosphorylation of IκBα, which is thought to require phosphoryla-
tion of IKKα/β. Therefore, it is possible that phosphorylation of IKKα/β is not required for
IKKα to phosphorylate IκBα or phosphorylation of IKKα/β occurs at levels undetectable in our
assays. Furthermore, we observe that although IκBα is phosphorylated in HCMV infected cells,
degradation of IκBα does not occur. We propose this may be due to the presence of a viral antag-
onist of canonical NF-κB signaling encoded by HCMV. For example, the human herpesvirus
varicella zoster virus encodes a protein (ORF61) that allows phosphorylation of IκBα, but inhib-
its IκBα degradation [43]. It is unknown if HCMV encodes a protein with a similar function.
We observe an increase in RelA-P(Ser536) over time in AD169 infected cells and suggest that
this is the result of phosphorylation of RelA by kinases such as IKKβ [3], not the result of canon-
ical NF-κB signaling per se. It has been reported that IKKβ is required for efficient productive
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AD169 replication [9,10]. It remains unknown how phosphorylation of RelA by IKKβ would
facilitate productive HCMV replication but inhibition of IKKβ can impair immediate early gene
expression [9,10]. This mechanism could be a confounding factor in the analysis of transcription
from promoters responsive to canonical NF-κB signaling in AD169 infected cells.
It remains unclear in what context canonical NF-κB signaling is required for either viral or
cellular transcription during productive HCMV replication as different HCMV strains and cell
types have been used in different studies. It is likely that canonical NF-κB signaling is utilized
by HCMV in only certain contexts. For example, canonical NF-κB signaling may be inhibited
in fibroblasts by the presence of HCMV NF-κB modulators UL138 and UL144, to prevent
anti-viral inflammatory responses [32]. As these proteins are encoded by low passage, but not
high passage, HCMV strains [32] this would, in part, explain strain-dependent differences in
NF-κB signaling. As Merlin(RCMV)1111) encodes the UL138 and UL144 it is likely Merlin
(RCMV)1111) inhibits NF-κB signaling. Therefore, the inability of BAY61-3606 to inhibit
Merlin(RCMV)1111) replication is consistent with a lack of NF-κB signaling in cells infected
with Merlin(RCMV)1111). However, canonical NF-κB signaling is required during dissemina-
tion of HCMV from macrophage [44].
We propose H3S10 phosphorylation by IKKα is required for efficient AD169 viral and cel-
lular gene expression and AD169 replication. H3S10 can also be phosphorylated by mitogen
and stress kinase 1 (MSK1) [45] and H3S10 phosphorylation by MSK1 can be found at the
MIEP during HCMV transcription in dendritic cells [46]. BAY61-3606 does not target MSK1
[22], but it is possible that the low levels of H3S10p seen in AD169 infected HFF cells treated
with either BAY61-3606 or IKKα siRNA is the result of H3S10 phosphorylation by MSK1. Pre-
liminary experiments from our laboratory indicate that H3S10 is phosphorylated in cells
infected with Merlin(RCMV1111) (data not shown). Importantly, as we did not observe inhibi-
tion of Merlin(RCMV1111) replication by BAY61-3606 it is possible that IKKα is not required
to phosphorylate H3S10 in Merlin(RCMV1111) infected cells. Rather, we speculate, MSK1 is
responsible for H3S10 phosphorylation in Merlin(RCMV1111) infected cells. Therefore, it
should be stressed that all histone modifications discussed here may be present in cells infected
with Merlin(RCMV1111), but the cellular factors required to mediate those histone modifica-
tions differ between HCMV strains.
Our study suggests H3S10p affects both viral and cellular transcription during productive
AD169 replication. It is possible that H3S10p is required for transcription from the MIEP as
treatment of AD169 infected cells results in a decrease in immediate-early protein production.
However, we propose that H3S10p may be of more importance for cellular transcription
required for AD169 replication, as profound decreases in AD169 replication contrast with rela-
tively modest decreases in immediate-early protein production in infected cells treated with
either BAY61-3606 or IKKα siRNA. A significant future challenge will be to map the localiza-
tion of H3S10p to viral and cellular promoters in HCMV infected cells and determine how
treatment of infected cells with either BAY61-3606 or IKKα siRNA affects the presence of
H3S10p at those promoters.
We initially hypothesized that the loss of H3S10p would lead to loss of H3K14ac. However,
we found no obvious effect on H3K14ac in AD169 infected HFF cells treated with either
BAY61-3606 or IKKα siRNA. It is unclear why there should be contrasting observations
between previous reports [16] and data presented here, but it is possible that there is an as yet
unrecognized mechanism in AD169 infected cells that ensures H3K14 acetylation takes place
in the absence of H3S10p.
It remains unknown how loss of H3S10p in AD169 infected cells directly or indirectly
affects virus replication. H3S10p has been used as a marker for mitosis. Thus, we considered
the possibility that loss of H3S10p in infected cells treated with either BAY61-3606 or IKKα
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siRNA is due to cell cycle arrest. However, we exclude this possibility as BAY61-3606 does not
inhibit a number of kinases that regulate mitosis [22] and we observed no obvious defect in cell
division of uninfected HFF cells treated with either BAY61-3606 or IKKα siRNA (data not
shown). Rather, we propose that loss of H3S10p could have pleiotropic effects in the infected
cell. Firstly, the lack of H3S10p at viral or cellular promoters could impact upon the recruit-
ment or removal of transcription factors from DNA. For example, the presence of H3S10p is
required for binding of 14-3-3 transcription factors to chromatin in the presence of H3K9ac
and H3K14ac [17] and H3S10p in the presence of H3K9me3 required to remove HP1, an
inhibitory factor which is known to have a role in inhibiting HCMV transcription from the
MIEP [47] and from promoters [48]. Also, H3S10p is required for chromatin condensation
[49]. During productive HCMV replication chromatin condensation must occur for chromatin
partitioning to take place [50,51]. This process condenses chromatin within the infected cell
nucleus providing space for the development of viral replication compartments, within which
viral genome replication occurs [51,52]. Thus, the loss of H3S10p may not allow the formation
or function of viral replication compartments.
We also observed that treatment of infected HFF cells with BAY61-3606 inhibits accumula-
tion of certain histone H3 acetylation and tri-methylation modifications not related to the pres-
ence of IKKα. The loss of these modifications, either alone or in combination, most likely
contributes to inhibition of AD169 replication by BAY61-3606 via an IKKα-independent
mechanism. It is unknown what proteins and pathways BAY61-3606 acts on to inhibit accu-
mulation of the H3 acetylation and tri-methylation modifications discussed above. Also, the
function of these histone H3 modifications in AD169 infected cells is unknown. Thus, the map-
ping of histone H3 acetylation and tri-methylation modifications affected by the presence of
BAY61-3606 to viral and cellular promoters will illuminate how these histone modifications
shape the transcriptional landscape required for virus replication. Moreover, BAY61-3606 may
prove to be a useful chemical tool to identify kinase proteins required for histone H3 acetyla-
tion and tri-methylation modification in HCMV infected cells.
Our observation that BAY61-3606 is an inhibitor of IKKα has relevance beyond the study
of HCMV replication. Firstly, the use of BAY61-3606 in experiments that implicate a role for
SYK and GCK in intracellular signaling that also involves IKKα should be reconsidered. Sec-
ondly, BAY61-3606 is structurally unrelated to widely available inhibitors of IKKα. Thus,
BAY61-3606 is a novel chemical scaffold from which novel IKKα inhibitors can be developed.
These compounds could be used as chemical tools to study topics such as pathogen replication
and the cellular response to inflammatory stimuli, plus have the potential to be used as novel
anti-infective therapeutics.
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